Literature DB >> 1292780

Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides.

S Matson1, A M Krieg.   

Abstract

Phosphodiester oligonucleotides are rapidly degraded in spleen cell cultures. The present studies were conducted to determine whether thymidine released from degradation of such oligonucleotides could be reutilized and compete with [3H]thymidine incorporation, thereby causing nonspecific inhibition of "proliferation" assays. Our studies in mitogen-stimulated mouse spleen cells demonstrate that "control" oligonucleotides that contain thymidine can cause more than 90% inhibition of [3H]thymidine incorporation. This inhibitory effect was generally dependent on the location of the thymidine within the oligonucleotide: oligonucleotides that had 3'-terminal thymidine(s) caused more suppression than those in which thymidines were at the 5' end. All oligonucleotides caused a modest but variable inhibition of [3H]uridine incorporation. Furthermore, [3H]thymidine incorporation was partially inhibited even by oligonucleotides that did not contain thymidine. We propose that investigators who use [3H]thymidine incorporation assays to assess antisense effects do so with caution. It may be prudent to use control oligonucleotides with the same number and location of thymidine bases and to confirm [3H]thymidine incorporation assays with other measures of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1292780     DOI: 10.1089/ard.1992.2.325

Source DB:  PubMed          Journal:  Antisense Res Dev        ISSN: 1050-5261


  5 in total

Review 1.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules.

Authors:  M V Corrias; F Guarnaccia; M Ponzoni
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.

Authors:  H J Andreyev; P J Ross; D Cunningham; P A Clarke
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Innate immune responses induced by CpG oligodeoxyribonucleotide stimulation of ovine blood mononuclear cells.

Authors:  Angelo Mena; Anil K Nichani; Yurij Popowych; Dale L Godson; Donna Dent; Hugh G G Townsend; George K Mutwiri; Rolf Hecker; Lorne A Babiuk; Philip Griebel
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

5.  The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.

Authors:  Jan L Bjersing; Kristina Eriksson; Andrej Tarkowski; L Vincent Collins
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.